Importantly, also endocrine therapies, such as aromatase inhibitors and androgen deprivation therapy, promote metabolic dysregulation, contributing to obesity, insulin resistance, and an increased risk of CVD. This evidence concerns the gene CYP19A1 and Insulin resistance.